Fibrin porous structure

Claim 2

Porous structure of fibrin or fibrinogen material, the structure comprising: in its substantially dry form, a compression strain of less than 8%, and a creep modulus higher than 1.5×10 6 Pa, said compression strain and creep modulus being measured for a sample having a diameter of 5 mm on which a compression of 2500 milli Newtons is exerted with a compression ramp of 500 milli Newtons per minute, after a compression release step following an initial compression of 2500 milli Newtons with a compression ramp of 500 milli Newtons per minute; and after hydration, such a porosity that at least 50% by volume of the total porosity is formed by channels with an open cross section of more than 500 μm 2 .

Claim 3

The structure of claim 1 , wherein the structure has after rehydration a compression strain of less than 8% and a creep modulus higher than 1.5×10 6 Pa, said compression strain and creep modulus being measured for a sample having a diameter of 5 mm on which a compression of 2500 milli Newtons is exerted with a compression ramp of 500 milli Newtons per minute, after a compression release step following an initial compression step of 2500 milli Newtons with a compression ramp of 500 milli Newtons per minute.

Claim 4

The structure of claim 1 further comprising a plurality of spaced walls defining cells therebetween, at least part of the cells are linked so as to define channels having after rehydration in cross section an open section greater than 500 μm 2 .

Claim 5

The structure of claim 1 having a density calculated in its substantially dry form of less than about 0.5 g/cm 3 .

Claim 6

The structure of claim 3 wherein the walls have a mean thickness of less than about 100 μm.

Claim 7

The structure of claim 1 having a surface area of less than about 1 m 2 /g after the structure is rehydrated.

Claim 8

The structure of claim 1 further comprising calcium and phosphorous within an atomic ratio Ca/P from about 0.5 to about 5.

Claim 9

The structure of claim 1 further comprising calcium which is substantially not bound to albumin.

Claim 10

The structure of claim 1 being substantially free of albumin.

Claim 11

The structure of claim 1 is substantially pyrogen free.

Claim 12

The structure of claim 3 further comprising a binding agent on at least a part of the surface of the cells.

Claim 13

The structure of claim 1 further comprising an additive being selected from the group consisting of antibody, antimicrobial agent, agent for improving the biocompatibility of the structure, proteins, anticoagulants, anti-inflammatory compounds, compounds reducing graft rejection, living cells, cell growth inhibitors, agents stimulating endothelial cells, antibiotics, antiseptics, analgesics, antineoplastics, polypeptides, protease inhibitors, vitamins, cytokine, cytotoxins, minerals, interferons, hormones, polysaccharides, genetic materials, proteins promoting the growth of endothelial cells on the fibrin, growth factors, cell growth factors, growth factors for heparin bond, substances against cholesterol, pain killers, collagen, osteoblasts, chondroblasts, chondrocytes, osteoclasts, hematpoeitic cells, stromal cells, osteoprogenitor cells, drugs, anti coagulants, poly DL lactate, alginate, recombinant material, triglycerides, fatty acids, C 12 -C 24 fatty acids, collagen, and mixtures thereof.

Claim 14

The structure of claim 1 , having a ratio of volume of the porous structure in its substantially dry form to the structure in its hydrated form of about 1.

Claim 15

The structure of claim 1 further comprising bone chips having a particle size of less than 2 mm.

Claim 16

The structure of claim 1 defining a powder having a grain size of less than about 1 mm.

Claim 17

A process for preparing a fibrin structure comprising the steps of: providing a solution containing at least about 5 mg/ml fibrin or fibrinogen; providing a calcium inhibiting agent; polymerizing the solution in the presence of the calcium inhibiting agent to cause at least partial cross-linking of the fibrin or fibrinogen materials to define a partially cross-linked fibrin or fibrinogen material; lyophilizing the partially cross-linked, fibrin or fibrinogen material to define a porous structure having the following physical characteristics: in its substantially dry form, a compression strain of less than 8% and a creep modulus higher than 1.5×10 6 Pa, the compression strain and creep modulus being measured for a sample having a diameter of 5 mm on which a compression of 2500 milli Newtons is exerted with a compression ramp of 500 milli Newtons per minute, after a compression release step following an initial compression of 2500 milli Newtons with a compression ramp of 500 milli Newtons per minute, and after hydration, a porosity such that at least 50% by volume of the total porosity is formed by channels with an open cross section of more than 500 μm 2 .

Claim 18

A process for preparing a fibrin structure comprising the steps of: providing a solution containing at least about 5 mg/ml fibrin or fibrinogen; providing a calcium inhibiting agent; polymerizing the solution in the presence of the calcium inhibiting agent to cause at least partial cross-linking of the fibrin or fibrinogen materials to define a partially cross-linked fibrin or fibrinogen material; lyophilizing the partially cross-linked, fibrin or fibrinogen material to define a porous structure having the following physical characteristics: in its substantially dry form, a compression strain of less than 8% and a creep modulus higher than 1.5×10 6 Pa, the compression strain and creep modulus being measured for a sample having a diameter of 5 mm on which a compression of 2500 milli Newtons is exerted with a compression ramp of 500 milli Newtons per minute, after a compression release step following an initial compression of 2500 milli Newtons with a compression ramp of 500 milli Newtons per minute, and after hydration, a porosity such that at least 50% by volume of the total porosity is formed by channels with an open cross section of more than 500 μm 2 .

Claim 19

The process of claim 16 , wherein the calcium inhibiting agent is present in an amount sufficient for reducing the cross-linking rate so as to obtain after the lyophilizing step a plurality of spaced walls defining therebetween channels, the channels having after rehydration in cross section an open section greater than 1000 μm 2 .

Claim 20

The process of claim 16 , wherein the calcium inhibiting agent is present in an amount sufficient for obtaining after the lyophilizing step a wall thickness of less than 100 μm.

Claim 21

The process of claim 16 , wherein the calcium inhibiting agent is selected from the group consisting of: citrate salts, phosphate salts, oxalate salts and mixtures thereof.

Claim 22

The process of claim 16 , wherein the polymerizing step includes an effective amount of the calcium inhibiting agent sufficient for increasing the clotting time to more than 30 seconds, said clotting time being measured at 37° C. in a stirred cuvette containing 0.5 ml of the fibrin or fibrinogen material.

Claim 23

The process of claim 16 , wherein the lyophilizing step is carried out at a temperature of less than 40° C. and at a pressure of less than 0.4×10 5 Pa.

Claim 24

The process of claim 16 further including the step of adding a phosphate salt to the solution in an amount sufficient for having a Ca/P ratio from about 0.5 to about 5.

Claim 25

The process of claim 16 wherein the solution is substantially free of albumin.

Claim 26

The process of claim 16 further comprising the step of adding to the solution prior to, during or after the polymerizing step a compound selected from the group consisting of: antibody, antimicrobial agent, agent for improving the biocompatibility of the structure, proteins, anticoagulants, anti-inflammatory compounds, compounds reducing graft rejection, living cells, cell growth inhibitors, agents stimulating endothelial cells, antibiotics, antiseptics, analgesics, antineoplastics, polypeptides, protease inhibitors, vitamins, cytokine, cytotoxins, minerals, interferons, hormones, polysaccharides, genetic materials, proteins promoting or stimulating the growth and/or attachment of endothelial cells on the cross-linked fibrin, growth factors, cell growth factors, growth factors for heparin bond, substances against cholesterol, pain killers, collagen, osteoblasts, chondroblasts, chondrocytes, osteoclasts, hematpoeitic cells, stromal cells, osteoprogenitor cells, drugs, anti coagulants, poly DL lactate, alginate, recombinant material, triglycerides, fatty acids, C 12 -C 24 fatty acids, and mixtures thereof or a solution containing at least one of said compound.

Claim 27

The process of claim 16 further comprising the step of after the lyophylizing step adding to the porous structure a compound selected from the group consisting of antibody, antimicrobial agent, agent for improving the biocompatibility of the structure, proteins, anticoagulants, anti-inflammatory compounds, compounds reducing graft rejection, living cells, cell growth inhibitors, agents stimulating endothelial cells, antibiotics, antiseptics, analgesics, antineoplastics, polypeptides, protease inhibitors, vitamins, cytokine, cytotoxins, minerals, interferons, hormones, polysaccharides, genetic materials, proteins promoting or stimulating the growth and/or attachment of endothelial cells on the cross-linked fibrin, growth factors, cell growth factors, growth factors for heparin bond, substances against cholesterol, pain killers, collagen, osteoblasts, chondroblasts, chondrocytes, osteoclasts, hematpoeitic cells, stromal cells, osteoprogenitor cells, anti coagulants, poly DL lactate, alginate, recombinant material, triglycerides, fatty acids, C 12 -C 24 fatty acids, drugs, and mixtures thereof or a solution containing at least one of said compound.

Claim 28

The process of claim 16 , wherein during the polymerizing step less than about 50% by weight of the fibrin or fibrinogen material is cross-linked.

Claim 29

The process of claim 16 , wherein the calcium inhibiting agent is an antibiotic having anticoagulant property.

Claim 30

The process of claim 16 , wherein the step of polymerizing is carried out at a pH from about 6 to about 10, and at a temperature from about 0° C. to about 60° C.

Claim 31

The process of claim 16 , wherein the structure can be sterilized at a temperature below 0° C. by gamma radiation at a dosage of at least about 25 kGys.

Claim 32

The process of claim 16 , wherein the porous material has an osmolarity greater than 175 mosm.

Claim 33

The process of claim 16 , further comprising the step of spray-freeze drying the porous structure.

Claim 34

A kit for preparing a bone substitute, said kit comprising a first chamber containing an aqueous solution containing BMP and a second container containing a fibrin or fibrinogen material having the following physical characteristics: in its substantially dry form, a compression strain of less than 8%, and a creep modulus higher than 1.5 10 6 Pa, said compression strain and creep modulus being measured for a sample having a diameter of 5 mm on which a compression of 2500 milli Newtons is exerted with a compression ramp of 500 milli Newtons per minute, after a compression release step following an initial compression of 2500 milli Newtons with a compression ramp of 500 milli Newtons per minute; and after hydration, such a porosity that at least 50% by volume of the total porosity is formed by channels with an open cross section of more than 500 μm 2 .

Claim 35

A kit for preparing a bone substitute, said kit comprising a first chamber containing an aqueous solution containing BMP and a second container containing a fibrin or fibrinogen material having the following physical characteristics: in its substantially dry form, a compression strain of less than 8%, and a creep modulus higher than 1.5 10 6 Pa, said compression strain and creep modulus being measured for a sample having a diameter of 5 mm on which a compression of 2500 milli Newtons is exerted with a compression ramp of 500 milli Newtons per minute, after a compression release step following an initial compression of 2500 milli Newtons with a compression ramp of 500 milli Newtons per minute; and after hydration, such a porosity that at least 50% by volume of the total porosity is formed by channels with an open cross section of more than 500 μm 2 .

Claim 36

A cement for use with bones comprising: a solution containing a fibrin powder, and bone particles, the fibrin powder having the following physical characteristics: in its substantially dry form, a compression strain of less than 8%, and a creep modulus higher than 1.5×10 6 Pa, said compression strain and creep modulus being measured for a sample having a diameter of 5 mm on which a compression of 2500 milli Newtons is exerted with a compression ramp of 500 milli Newtons per minute, after a compression release step following an initial compression of 2500 milli Newtons with a compression ramp of 500 milli Newtons per minute; and after hydration, such a porosity that at least 50% by volume of the total porosity is formed by channels with an open cross section of more than 500 μm 2 .

Claim 37

A cement for use with bones comprising: a solution containing a fibrin powder, and bone particles, the fibrin powder having the following physical characteristics: in its substantially dry form, a compression strain of less than 8%, and a creep modulus higher than 1.5×10 6 Pa, said compression strain and creep modulus being measured for a sample having a diameter of 5 mm on which a compression of 2500 milli Newtons is exerted with a compression ramp of 500 milli Newtons per minute, after a compression release step following an initial compression of 2500 milli Newtons with a compression ramp of 500 milli Newtons per minute; and after hydration, such a porosity that at least 50% by volume of the total porosity is formed by channels with an open cross section of more than 500 μm 2 .